Skip to main content
Log in

Increased haemorrhage risk with idraparinux leads to trial termination

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Amadeus Investigators.Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371: 315-321, No. 9609, 26 Jan 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Increased haemorrhage risk with idraparinux leads to trial termination. React. Wkly. 1187, 1 (2008). https://doi.org/10.2165/00128415-200811870-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811870-00001

Keywords

Navigation